Skip to content

The formulation of therapeutic plan for patients at high-risk of sepsis to regulate immune by ultrasound guided stellate ganglion block

The formulation of therapeutic plan for patients at high-risk of sepsis to regulate immune by ultrasound guided stellate ganglion block

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009706
Enrollment
Unknown
Registered
2016-11-01
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

ultrasound guided stellate ganglion block group:ultrasound guided stellate ganglion block with 7ml of 0.5% ropivacaine
control group:Injecting 7ml of saline at the place where the stellate ganglion is located

Sponsors

Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 60 patients with gastrointestinal surgery; 2) If there are any long-term medication history, drugs need to be clear, but there is no history of adrenaline receptors related drug medication.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) Patients suffering from chronic diseases, liver, kidney, cardiovascular disease;Psychosis or severe nerve recession; 3) Patients that fail to block stellate ganglion; 4) Have a bleeding tendency, the long-term use of antiplatelet or anticoagulant drugs; 5) Patients with immunosuppressive state.

Design outcomes

Primary

MeasureTime frame
The incidence rate of sepsis;the levels of inflammatory factor;

Secondary

MeasureTime frame
mortality rate of sepsis;length of stay in hospital;hospitalization costs;SOFA score;APACHEII score;CRP;PCT;

Countries

China

Contacts

Public ContactXiangming Fang

Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine

xiangming_fang@163.com+86 13857161019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026